Free Trial

JPMorgan Asia Growth & Income (JAGI) Competitors

JPMorgan Asia Growth & Income logo
GBX 377.95 -2.05 (-0.54%)
As of 11:48 AM Eastern

JAGI vs. BPCR, TRY, GSS, AGT, JFJ, ASHM, BRWM, IHP, BBGI, and JPE

Should you be buying JPMorgan Asia Growth & Income stock or one of its competitors? The main competitors of JPMorgan Asia Growth & Income include BioPharma Credit (BPCR), TR Property Investment Trust (TRY), Genesis Emerging Markets Fund (GSS), AVI Global Trust (AGT), JPMorgan Japanese (JFJ), Ashmore Group (ASHM), BlackRock World Mining Trust (BRWM), IntegraFin (IHP), BBGI Global Infrastructure (BBGI), and JPMorgan Elect plc ­- Managed Growth (JPE). These companies are all part of the "asset management" industry.

JPMorgan Asia Growth & Income vs. Its Competitors

JPMorgan Asia Growth & Income (LON:JAGI) and BioPharma Credit (LON:BPCR) are both small-cap financial services companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

JPMorgan Asia Growth & Income pays an annual dividend of GBX 16 per share and has a dividend yield of 4.2%. BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 791.9%. JPMorgan Asia Growth & Income pays out 32.6% of its earnings in the form of a dividend. BioPharma Credit pays out 7,957.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

29.9% of JPMorgan Asia Growth & Income shares are held by institutional investors. Comparatively, 41.5% of BioPharma Credit shares are held by institutional investors. 11.3% of JPMorgan Asia Growth & Income shares are held by insiders. Comparatively, 6.2% of BioPharma Credit shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

JPMorgan Asia Growth & Income has a net margin of 86.71% compared to BioPharma Credit's net margin of 80.20%. JPMorgan Asia Growth & Income's return on equity of 12.22% beat BioPharma Credit's return on equity.

Company Net Margins Return on Equity Return on Assets
JPMorgan Asia Growth & Income86.71% 12.22% -0.23%
BioPharma Credit 80.20%8.51%4.98%

JPMorgan Asia Growth & Income has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, BioPharma Credit has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500.

BioPharma Credit has higher revenue and earnings than JPMorgan Asia Growth & Income. JPMorgan Asia Growth & Income is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
JPMorgan Asia Growth & Income£41.43M6.68£35.93M£49.117.70
BioPharma Credit£12.99B0.08£10.42B£0.0910.05

In the previous week, BioPharma Credit's average media sentiment score of 1.32 beat JPMorgan Asia Growth & Income's score of 0.00 indicating that BioPharma Credit is being referred to more favorably in the news media.

Company Overall Sentiment
JPMorgan Asia Growth & Income Neutral
BioPharma Credit Positive

Summary

JPMorgan Asia Growth & Income and BioPharma Credit tied by winning 7 of the 14 factors compared between the two stocks.

Get JPMorgan Asia Growth & Income News Delivered to You Automatically

Sign up to receive the latest news and ratings for JAGI and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JAGI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

JAGI vs. The Competition

MetricJPMorgan Asia Growth & IncomeAsset Management IndustryFinancial SectorLON Exchange
Market Cap£276.87M£1.24B£6.45B£2.94B
Dividend Yield4.30%4.35%4.17%5.02%
P/E Ratio7.7021.9013.52140.04
Price / Sales6.682,386.361,774.76225,130.30
Price / Cash320.6860.8148.9127.99
Price / Book0.941.221.414.60
Net Income£35.93M£264.68M£1.25B£5.90B
7 Day Performance1.20%1.54%1.76%1.09%
1 Month Performance3.06%3.51%3.61%5.10%
1 Year Performance0.52%7.00%15.58%82.75%

JPMorgan Asia Growth & Income Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
JAGI
JPMorgan Asia Growth & Income
N/AGBX 377.95
-0.5%
N/A+1.0%£276.87M£41.43M7.70N/APositive News
BPCR
BioPharma Credit
N/AGBX 0.91
+0.7%
N/A+4.8%£1.08B£12.99B10.30N/APositive News
TRY
TR Property Investment Trust
N/AGBX 338
+1.7%
N/A+7.4%£1.07B£311.14M3.7826
GSS
Genesis Emerging Markets Fund
N/AN/AN/AN/A£1.06B£250.40M6.181,626Gap Down
AGT
AVI Global Trust
N/AGBX 239
+0.4%
N/A+0.4%£1.04B£219.59M4.80N/A
JFJ
JPMorgan Japanese
N/AGBX 630.48
-0.1%
N/A+22.0%£1.04B£198.16M5.32N/A
ASHM
Ashmore Group
N/AGBX 154
+0.9%
GBX 174
+13.0%
-6.3%£1.03B£199.65M10.91283
BRWM
BlackRock World Mining Trust
N/AGBX 530.90
+0.5%
N/A-6.9%£1.02B£8.73M-75.95147,000Positive News
IHP
IntegraFin
2.9984 of 5 stars
GBX 304
+0.5%
GBX 406.67
+33.8%
-7.7%£1.01B£138.65M19.283,520Positive News
Dividend Increase
BBGI
BBGI Global Infrastructure
N/AGBX 141.80
flat
N/AN/A£1.01B£67.98M18.361,160
JPE
JPMorgan Elect plc ­- Managed Growth
N/AN/AN/AN/A£1.00B£104.78M1,250.00N/ANews Coverage

Related Companies and Tools


This page (LON:JAGI) was last updated on 6/30/2025 by MarketBeat.com Staff
From Our Partners